Cambridge Antibody - Senior Managemnt Appointments
16 October 1997 - 10:25PM
UK Regulatory
RNS No 2829m
CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED
16th October 1997
Cambridge Antibody Technology
Senior Management Appointments
Cambridge Antibody Technology Limited (CAT) announces two
significant new appointments to its senior management
team.
Nigel Burns (BSc PhD) has joined as Vice President Pre-
Clinical Development. He was previously with British
Biotech where he was Head of Process Technology. Before
joining British Biotech he held scholarships in India at
The Central Drug Research Institute in Lucknow and at The
California Institute of Technology in the United States.
Nigel Burns is 37.
Diane Mellett (LLB JD) has joined as Vice President Legal
Affairs and will be Company Secretary of Cambridge
Antibody Technology Group plc. She previously worked
with Sonnenscheins in both London and Chicago and was a
founder member of their London office. She is a
qualified solicitor and admitted to the Illinois Bar.
Diane Mellett is 37.
Dr David Chiswell, Chief Executive Officer of CAT, said:
"This is another important step in building a strong
management team at CAT. Nigel Burns' experience
will benefit CAT significantly as we progress more
products towards the clinic and Diane Mellett's
professional background both here and in the United
States will be of great value in the Company's
commercial development. We are very pleased that
they are joining us."
For further information, please contact:
Cambridge Antibody Technology 01763 263233
David Chiswell Chief Executive Officer
John Aston Finance Director
Ludgate Communications 0171 253 2252
Andrew Nicolls
Nicola How
Notes to editors:
CAT
CAT's business is based on a world leading platform
technology for the rapid isolation of human monoclonal
antibodies. This technology has applications both in the
development of antibody-based human therapeutic products
and as a drug discovery tool, particularly in the context
of functional genomics.
CAT's strategy is to capitalise on the strength of its
platform technology in order to build a diverse portfolio
of antibody-based human therapeutic products. Clinical
trials of two human monoclonal antibodies developed by
CAT have started in 1997. Phase I/IIa Trials of CAT's
anti-TGF beta2 monoclonal antibody in patients with early
proliferative vitreo retinopathy have recently commenced,
and earlier this year Phase I/IIa trials of the human
anti-TNFalpha monoclonal antibody isolated and developed by
CAT in collaboration with Knoll (BASF) were initiated by
Knoll in patients with rheumatoid arthritis.
CAT will also continue to use its platform technology
as a drug discovery tool, to seek to secure licenses
and collaborative agreements with other pharmaceutical
companies, including genomics companies, thereby
gaining further access to antibody targets of potential
therapeutic interest.
CAT has already entered into a number of licence and
collaborative agreements with pharmaceutical and
biotechnology companies. These include: technology
licences with Genentech, Pfizer and Eli Lilly;
therapeutic antibody licences with Knoll (BASF),
Knoll(BASF)/Genetics Institute and Mitsubishi Chemical;
joint ventures with Techniclone and ObeSys (with BTG);
and a licence agreement with Integra Life Sciences.
END
MSCMLMMGZVRLNMM
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Oct 2023 to Oct 2024